US 12,466,894 B2Granted

Anti-MUC16 antibodies and uses thereof

AssigneeMemorial Sloan Kettering Cancer Center

InventorsDavid Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi

Life of this patent

Estimating the term…

Abstract

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Claims15

Dependent claims

An anti-MUC16 antibody conjugate comprising an anti-MUC16 antibody or antigen binding fragment conjugated to a payload, wherein the anti-MUC16 antibody or antigen binding fragment comprises:

(a) (i) a VH comprising a VH CDR1 comprising the amino acid sequence TX1GMGVG (SEQ ID NO:103), wherein X1 is L or V;
a VH CDR2 comprising the amino acid sequence HIWWDDX2DKYYX3PALKS (SEQ ID NO:104), wherein X2 is E or absent, and X3 is Y or N;
and a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:
105);
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence RSSKSLX4X5SNGNTYLY (SEQ ID NO:106), wherein X4 is R or L, and X5 is K or H;
a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107);
and a VL CDR3 comprising the amino acid sequence MQX6LEX7-PLT (SEQ ID NO:108), wherein X6 is G or S, and X7 is H or Y;
or
(b) (i) a VH comprising a VH CDR1 comprising the amino acid sequence GFSLX8TX9GM (SEQ ID NO:109), wherein X8 is N or S, and wherein X9 is L or V;
a VH CDR2 comprising the amino acid sequence WDDX10 (SEQ ID NO:110), wherein X10 is E or absent;
and a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111);
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence SKSLX11X12SNGNTY (SEQ ID NO:112), wherein X11 is L or R, and X12 is H or K;
a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113);
and a VL CDR3 comprising the amino acid sequence X13LEX14PL (SEQ ID NO:114), wherein X13 is G or S, and X14 is H or Y;
or
(c) (i) a VH CDR1 comprising the amino acid sequence GFSLX15TX16GMG (SEQ ID NO:115), wherein X15 is N or S, and X16 is V or L;
a VH CDR2 comprising the amino acid sequence IWWDDX17DK (SEQ ID NO:116), wherein X17 is E or absent;
and a VH CDR3 comprising the amino acid sequence X18RIGTAQATDALDY (SEQ ID NO:117), wherein X18 is T, A, or S;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence KSLX19X20SNGNTY (SEQ ID NO:118), wherein X19 is V or L, and X20 is H or K;
a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119);
and a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120);
or
(d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
88;
or
(e) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
94;
or
(f) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
100;
or
(g) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
28;
or
(h) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
34;
or
(i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
40;
or
(j) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
48;
or
(k) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
54;
or
(l) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
60;
or
(m) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
8;
or
(n) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
14;
or
(o) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
20;
or
(p) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
68;
or
(q) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
74;
or
(r) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
80.

80 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/375,048Filed 14 Jul 2021 · division
Priority: 17 Mar 2015
Published: US 2023/0026100 A126 Jan 2023
Granted: 11 Nov 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification29 codes

C07K 16/3092
Against structure-related tumour-associated moieties: against tumour-associated mucins
A01K 67/0275
New or modified breeds of vertebrates: genetically modified vertebrates, e.g. transgenic
A61K 39/0011
Vertebrate antigens: cancer antigens
A61K 39/00117
Tumor associated carbohydrates: mucins, e.g. MUC-1

Family

Application62/134,402Us provisional application · filed 17 Mar 2015
PCT/US2016/022643Parent of this division · filed 16 Mar 2016
US 2023/0026100 A1Pre-grant publication · published 26 Jan 2023
Application15/558,694Parent of this division
US 11,066,480 B2Parent of this division
US 2018/0112008 A1Published application
US 12,466,894 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An anti-MUC16 antibody conjugate comprising an anti-MUC16 antibody or antigen binding fragment conjugated to a payload, wherein the anti-MUC16 antibody or antigen binding fragment comprises:

(a) (i) a VH comprising a VH CDR1 comprising the amino acid sequence TX1GMGVG (SEQ ID NO:103), wherein X1 is L or V;
a VH CDR2 comprising the amino acid sequence HIWWDDX2DKYYX3PALKS (SEQ ID NO:104), wherein X2 is E or absent, and X3 is Y or N;
and a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:
105);
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence RSSKSLX4X5SNGNTYLY (SEQ ID NO:106), wherein X4 is R or L, and X5 is K or H;
a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107);
and a VL CDR3 comprising the amino acid sequence MQX6LEX7-PLT (SEQ ID NO:108), wherein X6 is G or S, and X7 is H or Y;
or
(b) (i) a VH comprising a VH CDR1 comprising the amino acid sequence GFSLX8TX9GM (SEQ ID NO:109), wherein X8 is N or S, and wherein X9 is L or V;
a VH CDR2 comprising the amino acid sequence WDDX10 (SEQ ID NO:110), wherein X10 is E or absent;
and a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111);
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence SKSLX11X12SNGNTY (SEQ ID NO:112), wherein X11 is L or R, and X12 is H or K;
a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113);
and a VL CDR3 comprising the amino acid sequence X13LEX14PL (SEQ ID NO:114), wherein X13 is G or S, and X14 is H or Y;
or
(c) (i) a VH CDR1 comprising the amino acid sequence GFSLX15TX16GMG (SEQ ID NO:115), wherein X15 is N or S, and X16 is V or L;
a VH CDR2 comprising the amino acid sequence IWWDDX17DK (SEQ ID NO:116), wherein X17 is E or absent;
and a VH CDR3 comprising the amino acid sequence X18RIGTAQATDALDY (SEQ ID NO:117), wherein X18 is T, A, or S;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence KSLX19X20SNGNTY (SEQ ID NO:118), wherein X19 is V or L, and X20 is H or K;
a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119);
and a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120);
or
(d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
88;
or
(e) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
94;
or
(f) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
100;
or
(g) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
28;
or
(h) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
34;
or
(i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
40;
or
(j) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
48;
or
(k) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
54;
or
(l) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
60;
or
(m) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
8;
or
(n) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
14;
or
(o) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
20;
or
(p) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
68;
or
(q) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
74;
or
(r) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77;
and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
80.

80 more elements

Facts

Application

17/375,048Filed 14 Jul 2021 · division

Priority

17 Mar 2015

Published

US 2023/0026100 A126 Jan 2023

Granted

11 Nov 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification29 codes

C07K 16/3092
Against structure-related tumour-associated moieties: against tumour-associated mucins
A01K 67/0275
New or modified breeds of vertebrates: genetically modified vertebrates, e.g. transgenic
A61K 39/0011
Vertebrate antigens: cancer antigens
A61K 39/00117
Tumor associated carbohydrates: mucins, e.g. MUC-1

Family

Application62/134,402Us provisional application · filed 17 Mar 2015

PCT/US2016/022643Parent of this division · filed 16 Mar 2016

US 2023/0026100 A1Pre-grant publication · published 26 Jan 2023

Application15/558,694Parent of this division

US 11,066,480 B2Parent of this division

US 2018/0112008 A1Published application

US 12,466,894 B2This patent

From the US filing history. Foreign family members aren’t listed.